- Home
- EYPT
as 01-17-2025 4:00pm EST
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 594.5M | IPO Year: | 2005 |
| Target Price: | $25.71 | AVG Volume (30 days): | 922.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.90 - $30.99 | Next Earning Date: | 03-06-2025 |
| Revenue: | $45,713,000 | Revenue Growth: | 7.50% |
| Revenue Growth (this year): | -5.25% | Revenue Growth (next year): | -63.95% |
Latest EyePoint Pharmaceuticals Inc. News
EYPT Breaking Stock News: Dive into EYPT Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
6 days ago
EyePoint Provides Company Update and Anticipated Development Milestones for 2025
GlobeNewswire
11 days ago
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors
MT Newswires
12 days ago
Citigroup Initiates EyePoint Pharmaceuticals at Buy With $33 Price Target
TipRanks
a month ago
EyePoint reports inducement grants under NASDAQ listing rule
GlobeNewswire
a month ago
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
a month ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TipRanks
a month ago
EyePoint doses first patient in second Phase 3 LUCIA clinical trial
Compare EYPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.